NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NB-4746’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NB-4746 overview

Small molecules are under development for the treatment of amyotrophic lateral sclerosis, multiple sclerosis (MS), traumatic brain injury (TBI), and chemotherapy-induced peripheral neuropathy (CIPN). The drug candidates act by targeting sterile alpha and TIR motif containing protein 1 (SARM1) protein. It is administered through oral route.

Nura Bio overview

Nura Bio is a biotechnology company focusing on treatment of central, peripheral, and ocular neurological diseases. The Column Group and its scientific founders came up with the idea for Nura Bio, with the goal of revolutionizing the treatment of neurological disorders with surface, innovative neuroprotective drugs. It aims to restore hope for those suffering from severe neurological diseases by developing neuroprotective drugs using recent scientific breakthroughs in axonal degeneration and neuroimmune regulation. Several peripheral, central, and ocular nervous system diseases include early symptoms that include axon degeneration and neuronal loss. The company is headquartered in South San Francisco, California, the US.

For a complete picture of NB-4746’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.